Abstract
Introduction
When the kidneys are no longer able to work at a level needed for day-to-day life, then we label the disease as end stage kidney disease (ESKD). Dialysis and kidney transplantation, of the two treatment modalities, kidney transplantation has become the preferred option for ESKD patients. In 1936, Dr. Voronoy, a Russian, reported the first human-to-human, mismatched, non related kidney transplant and in 1954 Surgeons Joseph E. Murray and John Hartwell Harrison, in collaboration with nephrologist John P. Merrill, performed the first successful kidney transplant, between identical twins, at the Peter Bent Brigham Hospital in Boston. 1 Fifty years later, in 2004, in BIRDEM General Hospital, live related donor renal transplant was started. So far we have performed 111 live related donor kidney transplant in the last 10 years. Here we share our experiences of the past decade.
Methods
During renal transplantation, consent was taken from every patient regarding storage of all medical data and possible use for scientific research without disclosing their identity. In this study no intervention was planned and identity of the recipients was not disclosed.
Data were collected in a pre-formed questionnaire from the hospital records. We retrospectively evaluated patients' clinical and laboratory findings.
Results
In the past decade, 111 live related donor renal transplants were done in our unit. Of them, 77 (69.4%) were male and 34 (30.6%) were female. The mean age of the recipients was 37.45 ± 10.58 years (range 18 to 62 years). Most patients (40, 36.04%) were from the age group of 31 to 40 years ( Figure 1 ). As cause of ESKD, highest number of patients (52, 46.9%) were suffering from chronic glomerulonephritis (CGN) and the others were diabetes mellitus (DM) (31, 27.9%), hypertension (26, 23.4%), chronic pyelonephritis (1, 0.9%) and obstructive nephropathy (1, 0.9%). Preemptive transplantation was done in 4 (3.6%) patients. Before transplantation, 2 (1.8%) patients were receiving continuous ambulatory peritoneal dialysis (CAPD) and 105 (94.6%) were on maintenance haemodialysis. As donors, siblings stepped forward in most of the cases [brother 42 (37.8%) and sister 20 (18.0%)]. Donor relationships among the rest of the cases were, mother 19 (17.1%), uncle 18 (16.3%), aunty 6 (5.4%), wife 3 (2.7%), father 2 (1.8%) and daughter 1 (0.9%). Majority of the recipients had an uncomplicated recovery (72, 64.9%). The most common complications during posttransplant hospital stay were infections (27.0%). A total of 30 incidences of infections were detected with the following distribution -urinary tract infection (24, 21.6%), respiratory tract infection (2, 1.8%), septicaemia (2, 1.8%), cylomegato virus infection (1, 0.9%) and wound infection (1, 0.9%). Other complications were renal vein thrombosis (1, 0.9%), haemolytic uremic syndrome [HUS] (1, 0.9%), acute tubular necrosis [ATN] (1, 0.9%), peri-renal collection (1, 0.9%), pericardial effusion (1, 0.9%) and clot retention in urinary bladder (2, 1.8%). Surgical failure was experienced in 1 (0.9%) and acute rejection was .27 days (range 9 to 30 days). Mean serum creatinine during discharge was 1.33 ± 0.74 mg/ dl (range 0.7 to 3.8 mg/dl) and mean time from surgery to normalization of serum creatinine was 5.75 ± 4.15 days (range 2 to 26 days). We discharged 79 (71.2%) patients with normal renal function (mean serum creatinine 1.03 ± 0.15 mg/dl). In 29 (26.1%) patients serum creatinine was improving but did not reached normal level (mean serum creatinine 2.01 ± 1.04 mg/ dl).
As induction, 61 (54.95%) patients received injection basiliximab and as maintenance therapy all patients In the first year of transplant, 49 (49.5%) patients suffered from 59 episodes of infection. The pattern and aetiological agents of infections are plotted in Table I and II respectively.
Incidence of chronic allograft nephropathy in CGN, DM and hypertension patients were 25% (13/52), 19.4% (6/ 31) and 23.1% (6/26) respectively.
In this center, patient and graft survival at 1 year was 98.1% (99) and 94.06% (95) respectively. Also patient and graft survival at 5 years was 84.09% (37) and 77.27% (34) respectively. Five (4.5%) patients dropped out from follow-up.
Discussion
The outcome for kidney transplant recipients has markedly improved since it was started. This improvement of outcome is due to various reasons. First, development of more improved criteria for selection of recipients as well as donors; second, development of appropriate immunosuppressive protocol; third, discovery and usage of new and less toxic but efficient immunosuppressive drugs; forth, introducing induction therapy; and lastly awareness and development of management strategy about infections and other posttransplant complications of the recipients. 3,6-8, 11, 14 These developments lead us to select more suitable patients as recipients and perfectly matched healthy donors for them. Fewer cases of acute rejection are faced now-a-day, due to appropriate induction therapy and immunosuppressive protocol. The induction therapy also has a role in long term graft survival along with usage of newer, effective and less toxic drugs as post transplant immunosuppressive agents. 15 Awareness about comorbid conditions and infection and other posttransplant complications help us to address them promptly and properly, so that the patient as well as the graft longevity is less influenced. The reflection of all these can be seen in the results of our unit.
The graft survival at 1 and 5 years ranges from 91% to 98.3% and 68% to 92.5% respectively in different transplant centers of the world. On the other hand, patient survival of these centers at 1 and 5 years ranges from 97% to 99.4% and 82.2% to 93.7% respectively. Our graft and patient survival at 1 year was 94.1% and 98.1% respectively and at 5 years was 77.3% and 84.1% respectively, which is comparable to or, in some aspects, even better in comparison to other centers of both developing and developed world (Table III and  Table IV) .
After 10 years, the reflection of outcome of live related donor renal transplant in a center of a developing country like ours, with limited facility and resources, is still encouraging. During these 10 years we have to construct a smooth platform to face this type of advanced challenges and overcome the restriction of resources. This will encourage us to provide better and advanced management to the emerging number of ESKD patients with success.
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